| EVIDENCE
WATCH
A review and assessment of recent
clinical trial data
Renal
cancer
PHASE III RANDOMIZED TRIAL OF SUNITINIB MALATE (SU1 1248)
VERSUS INTERFERON-ALFA (IFN-a) AS FIRST-LINE SYSTEMIC THERAPY
FOR PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC).
ASCO 2006, ABSTRACT LBA3.
TEMSIROLIMUS (TEMSR) OR INTERFERON-ALPHA
(IFN) OR THE COMBINAT ION OF TEMSR + IFN IN THE TREATMENT
OF FIRST-LINE, POOR-RISK PATIENTS WITH ADVANCED RENAL CELL
CARCINOMA (ADV RCC). ASCO 2006, ABSTRACT LBA4.
Colorectal
cancer — intermittent chemotherapy
OPTIMOX2, A LARGE RANDOMIZED PHASE II STUDY OF MAINTENANCE
THERAPY OR CHEMOTHERAPY-
FREE INTERVALS (CFI) AFTER FOLFOX IN PATIENTS WITH METASTATIC
COLORECTAL CANCER (MRC). A GERCOR STUDY. ASC0 2006, ABSTRACT
3504.
ALTERNATING VERSUS CONTINUOUS “FOLFIRI”
IN ADVANCED COLORECTAL CANCER (ACC):
A RANDOMIZED “GISCAD” TRIAL. ASCO 2006, ABSTRACT
3505
Breast
cancer: neoadjuvant chemotherapy
SWOG 0012, A RANDOMIZED PHASE III COMPARISON OF STANDARD DOXORUBICIN
(A) AND
CYCLOPHOSPHAMIDE (C) FOLLOWED BY WEEKLY PACLITAXEL (T) VERSUS
WEEKLY DOXORUBICIN AND DAILY ORAL CYCLOPHOSPHAMIDE PLUS G-CSF
(G) FOLLOWED BY WEEKLY PACLITAXEL AS NEOADJUVANT THERAPY FOR
INFLAMMATORY AND LOCALLY ADVANCED BREAST CANCER.
ASCO 2006, ABSTRACT LBA537.
Breast
cancer: chemotherapy-related cardiotoxicity
CONGESTIVE HEART FAILURE (CHF) IN OLDER WOMEN TREATED WITH
ANTHRACYCLINE (A)
CHEMOTHERAPY (C). ASCO 2006, ABSTRACT 521.
LONG TERM CARDIAC TOLERABILITY OF TRASTUZUMAB
IN HER-2-OVEREXPRESSING
METASTATIC BREAST CANCER (MBC). ASCO 2006, ABSTRACT 629.
Breast
cancer: switching hormonal therapies
MORTALITY BENEFIT OF SWITCHING TO AN AROMATASE INHIBITOR IN
EARLY BREAST CARCINOMA:
POOLED ANALYSIS OF TWO CONSECUTIVE TRIALS. ASCO 2006, ABSTRACT
548.
SURVIVAL BENEFIT OF SWITCHING TO ANASTROZOLE
AFTER 2 YEARS’ TREATMENT WITH TAMOXIFEN VERSUS CONTINUED
TAMOXIFEN THERAPY: THE ARNO 95 STUDY.
ASCO 2006, ABSTRACT 547.
FIRST MATURE ANALYSIS OF THE INTERGROUP
EXEMESTANE STUDY.
ASCO 2006, ABSTRACT LBA527.
Breast
cancer: hormonal therapies and bone health
ANALYSIS OF FRACTURE RISK FACTORS FROM THE ‘ARIMIDEX’,
TAMOXIFEN,
ALONE OR IN COMBINATION (ATAC) TRIAL: 5-YEAR DATA . ASCO 2006,
ABSTRACT 563.
EFECT OF ANASTROZOLE ON BONE MINERAL
DENSITY: 5-YEAR RESULTS FROM THE ‘ARIMIDEX’,
TAMOXIFEN, ALONE OR IN COMBINATION (ATAC) TRIAL. ASCO 2006,
ABSTRACT 511.
Breast
cancer: biological therapies and EGFR
SERUM HER-2/NEU CHANGE PREDICTS CLINICAL OUTCOME TO TRASTUZUMAB-BASED
THERAPY.
ASCO 2006, ABSTRACT 500.
EGFR EXPRESSION IN BREAST CANCER: ASSOCIAT
ION WITH BIOLOGIC PHENOTYPE,
PROGNOSIS, AND RESISTANCE TO ADJUVANT THERAPY. ASCO 2006,
ABSTRACT 513.
PHASE II TRIAL OF LAPATINIB FOR BRAIN
METASTASES IN PATIENTS WITH HER2+ BREAST CANCER.
ASCO 2006, ABSTRACT 503.
Breast
cancer: biomarkers predicting chemotherapy effect
HER2 PREDICTS BENEFIT FROM ADJUVANT PACLITAXEL AFTER AC IN
NODE-POSITIVE BREAST CANCER: CALGB 9344. ASCO 2006, ABSTRACT
510.
TOP2A ABERRAT IONS AS PREDICTIVE AND
PROGNOSTIC MARKER IN HIGH-RISK BREAST CANCER PATIENTS. A RANDOMIZED
DBCG TRIAL (DBCG89D). ASCO 2006, ABSTRACT 532.
| 
